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ABSTRACT
Introduction: Intense nocturnal pruritus as
well as the complex pathophysiology of atopic
dermatitis (AD) can severely affect sleep and
become a major factor in negatively impacting
quality of life in adults. However, much of the
literature on sleep disturbance in AD patients is
on the pediatric population, and it is not well
studied in adults. Furthermore, limited studies
are available to guide effective management of
sleep disturbance in AD in general. We review
the literature to present the studies that have
investigated the relationship between AD and
its effect on sleep in adults and provide an
approach for clinicians caring for this
population.
Methods: A systematic literature search was
conducted through the PubMed and EMBASE
databases using the search terms ‘‘atopic der-
matitis’’ OR ‘‘eczema’’ AND ‘‘sleep.’’ The articles
generated by the search and their references
were reviewed.
Results: A high prevalence of sleep disturbance
is experienced by adults with AD. The likeli-
hood of sleep disturbance is much higher in
patients with AD compared to those without
AD. Sleep disturbance appears to worsen with
AD severity. Pruritus and scratching appear to
be large contributors to sleep disturbance in
adult patients with AD.
Conclusion: It is important that clinicians
evaluate the severity of AD and ask general
questions about itching, sleep, impact on daily
activities, and persistence of disease during each
patient visit and follow-up with the complaint
of sleep disturbance. Management of sleep dis-
turbance in AD should focus on adequate dis-
ease control of AD as well as possible medical
interventions to help improve sleep. The
pathophysiology of sleep disturbance in AD is
extremely complex, and further research is
needed to better understand the interplay of the
immune system, circadian rhythm, and envi-
ronmental factors implicated in both AD and
sleep.
Keywords: Adults; Atopic; Dermatitis;
Disturbance; Eczema; Sleep
INTRODUCTION
Atopic dermatitis (AD), commonly known as
eczema, is a chronic relapsing inflammatory skin
disease characterized by pruritus, erythema, and
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lichenified lesions of the skin. The pathogene-
sis of AD is complex and involves genetic
predisposition, a hyperactive immune system,
and environmental factors [1]. While AD most
frequently affects children, it is a disease that
can persist into adulthood or have adult onset.
The prevalence in US adults is estimated to be
7.2% [2, 3].
Pruritus is an early characteristic symptom of
AD, so much so that AD is known as ‘‘the itch
that rashes’’ [4]. AD is commonly associated
with intense nocturnal pruritus, which can
affect sleep and quality of life (QoL) [5, 6]. Sleep
insufficiency can lead to excessive daytime
sleepiness, mood disturbance, and impaired
cognition [7], which can then have an impact
on work or school productivity, accidents, and
adverse health outcomes including metabolic,
endocrine, and immune dysregulation such as
type 2 diabetes, hypertension, and infection
[8–12].
Both qualitative and quantitative analyses of
sleep disturbance in patients with AD are valu-
able for the evaluation of disease activity and
response to therapy. Much of the current liter-
ature focuses on sleep disturbance in pediatric
patients with AD using qualitative assessments
based on subjective surveys [13]. In general,
discrepancies between subjective and objective
measurements of sleep have been previously
reported [14, 15]. For example, adults with
nocturnal asthma reported reduced overall
sleep quality compared to control subjects but
not increases in frequency of awakenings (sub-
jective) even though polysomnographic mea-
surement revealed differences in sleep latency,
efficiency, and awakenings (objective) [16]. The
topic of sleep disturbance in adult AD patients is
not well studied. We reviewed the literature for
studies that have investigated the relationship
between AD and its effect on sleep in adults.
METHODS
A systematic literature search was conducted
through the PubMed and EMBASE databases
using the search terms ‘‘atopic dermatitis’’ OR
‘‘eczema’’ AND ‘‘sleep.’’ The search terms were
used to find peer-reviewed journal articles
published between 1980 and 20 December
2016. The literature search was limited to
human adult (C18 years of age) studies written
in English. Each article resulting from the liter-
ature search was screened primarily by three
authors for content by reading the abstract.
Original investigations focusing on sleep dis-
turbance in adults with AD were chosen for
further review. The references of these articles
were searched for other relevant articles and
reviewed. Review articles, case series/reports,
and commentaries were excluded. Articles were
organized under five sections: ‘‘I. Methods Used
to Assess Sleep Disturbance’’, ‘‘II. Association of
AD with Sleep Disturbance’’, ‘‘III. Specific Alter-
ations of Sleep Identified in AD’’, ‘‘IV. Associa-
tion of AD with Impaired Functioning and
Quality of Life’’, and ‘‘V. Treatment Strategies
for Sleep Disturbance in Adults with AD’’. Some
articles fell under multiple categories. This
article is based on previously conducted studies
and does not involve any new studies of human
or animal subjects performed by any of the
authors.
RESULTS
The PubMed and EMBASE database search yiel-
ded a total of 250 articles. Of these, 39 articles
were deemed relevant and were original inves-
tigations on sleep disturbance in adults with AD
that focused on at least one of five parameters
outlined above. The summary of the results is
shown in Table 1.
I. Methods Used to Assess Sleep
Disturbance
Questionnaires
A number of studies in the literature assessed for
sleep disturbance using qualitative assessments
based on subjective surveys [2, 17–23]. How-
ever, a more in-depth assessment of sleep was
reported in other studies using a specific sleep
questionnaire using the Pittsburg Sleep Quality
Assessment (PSQI) [19, 24–27]. This is a vali-
dated, self-reporting questionnaire to measure
the quality and patterns of sleep in adults [28].
It is composed of seven components that
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evaluate the quality of sleep in adults: (1) sub-
jective sleep quality, (2) sleep latency, (3) sleep
duration, (4) habitual sleep efficiency, (5) sleep
disturbance, (6) use of sleeping medication, and
(7) daytime dysfunction (Table 2). Ranging
from 0 to 21 points, a higher PSQI score is
indicative of more disturbed sleep. A limitation
of PSQI is the reliance on self-reported data,
which may be affected by recall bias.
Actigraphy
Actigraphy is a small, wrist-worn device that
estimates sleep-wake patterns (sleep latency,
efficiency, and periods of awakening) by using
activity-based monitoring. It has been validated
to assess sleep parameters and highly correlates
with polysomnography [24]. Actigraphy may be
the preferred method of assessing sleep in AD
because it reflects the home environment, is
easy to use, is cost-effective, and assesses the
most common parameters of sleep affected in
patients with AD (e.g., sleep disruption sec-
ondary to nocturnal awakenings and scratch-
ing) [29]. In this review, we identified a small
number of studies using actigraphy
[26, 27, 29, 30].
Polysomnography
The components of polysomnography (PSG)
include the electroencephalogram (EEG), elec-
trooculogram (EOG), and electromyogram
(EMG), which together make up the gold stan-
dard of sleep examinations. From this literature
search, only a small number of studies used PSG
to assess sleep in adults with AD [26, 27, 31, 32].T
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Table 2 The seven components of the Pittsburg Sleep
Quality Assessment (PSQI)
Pittsburg sleep quality assessment (PSQI)
1. Subjective sleep quality
2. Sleep latency
3. Sleep duration
4. Habitual sleep efficiency
5. Sleep disturbance
6. Use of sleeping medication
7. Daytime dysfunction
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Utilizing PSG can be difficult because of the
inconvenience of having to stay overnight at a
sleep center and the discomfort of having mul-
tiple leads and equipment attached, especially
for patients with AD who may experience more
skin irritation.
II. Association of AD with Sleep
Disturbance
Estimated Prevalence of Sleep Disturbance
in AD
Current published data based on surveys of AD
patients suggest that 33–87.1% of adults with
AD suffer from sleep disturbance based on sur-
veys of AD patients [17, 18, 20].
Risk of Sleep Disturbance in AD
A survey-based study by Yu et al. [17] demon-
strated that adult patients with AD had a higher
likelihood of sleep disturbance compared to
those without AD, including specific measures
such as shorter sleep time, trouble falling asleep,
nighttime awakenings, and early morning
awakenings (Fig. 1). Adult AD patients also have
higher odds of feeling unrested, overly sleepy,
and as if they did not get enough sleep. This
study did not report any significant association
between AD and clinical diagnosis of a sleep
disorder. Another survey-based study by Silver-
berg et al. [2] found that adult AD patients are
more likely to suffer from insomnia (OR: 2.36;
P\0.0001) compared to adults without AD. A
number of studies using general QoL surveys
[e.g., the Dermatology Quality Life Index
(DLQI)] also found an association between AD
and sleep disturbance [2, 17, 19, 24, 25].
Correlation Between Sleep Disturbance
and AD Severity
Studies that investigated the relationship
between AD severity and degree of sleep dis-
turbance showed mixed results. Yano et al. [19]
found significant correlation between SCORing
Atopic Dermatitis (SCORAD) and PSQI
(P\0.0003), while Kong et al. [24] found only
the pruritus score of SCORAD to correlate with
PSQI (P\0.001). However, Misery et al. [22]
found no significant correlation with between
SCORAD and daytime sleepiness (P\0.15).
Sanchez-Perez et al. [20] reported difficulty
falling asleep in up to 76.2% of adult AD
patients with mild disease, 89% with moderate
disease, and 100% with severe disease, based on
the modified Eczema Area and Severity Index
(mEASI). Furthermore, 54.8% of patients with
mild disease, 76.2% with moderate disease, and
Fig. 1 Risk of sleep disturbance in atopic dermatitis according to Yu et al. [17]
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92.6% with severe disease reported waking up
from sleep because of pruritus.
Studies measuring sleep using actigraphy
showed a positive correlation between AD dis-
ease severity and degree of sleep disturbance
[26, 29].
III. Specific Alterations of Sleep Identified
in AD
Sleep Latency, Sleep Efficiency, and Normal
Sleep Stages
The term ‘‘sleep latency’’ refers to the time
between going to bed and sleep onset. The term
‘‘sleep efficiency’’ refers to the proportion of
time in bed that is spent sleeping. After entering
sleep, there is a cyclic alteration every 90 min
between two states: non-rapid eye movement
(NREM) and rapid eye movement (REM) sleep
[33]. The first third of the night has a higher
proportion of NREM and is essential for
restorative sleep. NREM has stages N1, N2, and
N3. The arousal threshold is lowest in N1 and
highest in N3. The arousal threshold in N2 is
similar to the REM state. There is a higher pro-
portion of REM sleep during the last third of the
night, which is associated with dreaming and
minimal muscle tone activity.
Sleep Latency in AD Patients
Jernelov et al. [21] reported that the adult AD
group had longer sleep latencies based on
self-reported surveys (P\0.05). On the other
hand, Bender et al. [27] demonstrated that there
were no significant differences in sleep latency
(P = 0.10) in adult AD patients using PSQI.
Scratching During Sleep in AD Patients
Studies using multiple methods for assessing
sleep show that scratching mainly occurs in
earlier stages of sleep, specifically the N1 and N2
stages [26, 31]. Bender et al. [26] used PSG to
demonstrate that scratching correlates with
lower sleep efficiency (P = 0.01). Noro et al.
[34], using a novel wristwatch sound detector,
showed that the ratio of scratching duration to
total sleeping time is significantly higher in AD
patients than in control subjects (7.51% vs.
0.40%; P\0.05) and the mean scratching
duration is more than ten times higher in AD
patients (P\0.05). Ebata et al. [32, 35] used
video monitoring and observed longer dura-
tions of scratching and being awake after a
scratching bout rather than increased frequency
of scratching during sleep in AD patients. Fur-
thermore, using PSG, Aoki et al. [31] demon-
strated that the act of scratching during sleep
brought the patients to a more superficial stage
of sleep. Similarly, Ebata et al. [35] found that
patients usually turned over or woke up after a
scratching bout. Bringhurst et al. [30] found
that the median number of movements during
sleep is twice as high in AD patients vs. control
subjects (P\0.001) using actigraphy.
Sleeping Time in AD Patients
A number of studies have shown conflicting
results on sleep time in AD. Bender et al. [27],
using actigraphy, demonstrated that AD
patients slept less (402 vs. 441 min; P\0.05),
awoke more often (13.9 episodes vs. 7.2 epi-
sodes; P\0.03), and spent more time awake
during waking episodes (4 vs. 2 min; P = 0.02)
compared to control subjects. However, the
authors did not find significant differences in
sleep duration using PSQI (P = 0.10). In addi-
tion, Bender et al. [26] demonstrated that dif-
ferences in sleep efficiency were not statistically
significant (P = 0.09). Similarly, another study
by Noro et al. [34] using overnight video
observation observed no significant difference
in the mean sleeping time between AD patients
and controls.
Sleep Quality in AD Patients
Bender et al. [27] demonstrated that the mean
PSQI score of adult AD patients was significantly
higher than controls (P\0.05) and reported
lower sleep quality and more awakenings. In
contrast, based on survey data, Jernelov et al.
[21] reported that sleep quality between the AD
group and control group was similar.
Other Findings
A study by Yu et al. [17] using self-reported
surveys found that higher occurrence of leg
jerks (OR: 2.49; P = 0.004) and leg cramps
(OR: 3.96; P = 0.001) during sleep were
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reported by AD patients vs. control subjects.
There was no significant association between
AD and snoring or cessation of breathing (OR:
1.64; P = 0.18).
IV. Association of AD with Impaired
Functioning and Quality of Life
Impact of Sleep Disturbance on Functioning
Using the PSQI, Bender et al. [26] showed that
there was more daytime dysfunction in AD
patients with sleep disturbance vs. control
subjects (P\0.05). According to survey data
by Silverberg et al. [2], AD patients with sleep
disturbance had higher numbers of missed
workdays, days in bed, and doctor visits than
those with either eczema or sleep disturbances
alone (P\0.0001 for all). Furthermore, Yu
et al. [17] demonstrated that AD patients who
reported being tired were more likely to have
difficulty with instrumental activities of daily
living (IADLs), including concentrating (OR:
1.61; P = 0.01), remembering (OR: 1.85;
P = 0.004), eating (OR: 2.90; P = 0.001), per-
forming hobbies (OR: 2.36; P = 0.001), doing
finances (OR: 2.56; P = 0.001), and driving
and/or navigating public transportation (OR:
1.99; P = 0.004).
Impact of Sleep Disturbance on QoL
Kong et al. [24] and Beikert et al. [25] found a
significant correlation between PSQI and DLQI
in AD patients (P = 0.04, P = 0.00, respectively).
Yano et al. [19] found that subjective sleep
quality (P\0.001), latency (P\0.001), habitual
sleep efficiency (P\0.05), sleep disturbance
(P\0.01), and daytime dysfunction (P\0.001)
are correlated with lower DLQI scores. Duration
of sleep and sleep medication use did not cor-
relate with DLQI. Furthermore, survey data by
Terreehorst et al. [23] demonstrated that the
severity of sleepiness has a significant negative
effect on QoL, including mental health
(P\0.01) and social functioning (P\0.01).
V. Treatment Strategies for Sleep
Disturbance in Adults with AD
In general, most studies examining treatment of
AD do not specifically address the ‘‘sleep’’ com-
ponent; thus, the data are very limited. Our
findings on the treatment of sleep from the lit-
erature are summarized in Fig. 2.
Topical Therapy
Weber et al. [36] demonstrated that emollients
are important in the daily skin care of adult
Fig. 2 Summary of the treatment of sleep in atopic dermatitis (AD) patients from the literature. Asterisk affected by AD.
SCORAD SCORing Atopic Dermatitis
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patients with AD and can significantly improve
itch (P\0.001). Abeck et al. [37] demonstrated
that basic emollients in combination with
chlorhexidine-soaked dressing ‘‘wet wrap’’
improved itch and sleep loss in AD patients
(adults and children).
Another study by Peserico et al. [38]
demonstrated that the use of methylpred-
nisolone aceponate (MPA) cream combined
with an emollient as maintenance therapy is an
effective regimen with reduction in risk of
relapse (HR: 3.5; P\0.0001), stable mainte-
nance of low intensity of itching (P\0.0001),
and relatively stable maintenance of sleep
quality (significance of data was not shown)
compared to the emollient alone in moder-
ate-to-severe AD adult and adolescent patients.
Light Therapy
Becker et al. [39] demonstrated that blue light
total body irradiation of severe, chronic AD
significantly improved pruritus and sleep dis-
turbance (P\0.003 for both).
Antihistamines
Antihistamines are widely used as a therapeutic
adjunct in patients with AD to treat pruritus
[40]. First-generation antihistamines are often
used for sleep problems in AD patients, most
likely because of their sedating effects [41].
However, the evidence to support their use in
AD patients is relatively weak since no large,
randomized, placebo-controlled clinical trials
with definitive conclusions have been per-
formed [42]. For adults, O’Donoghue et al. [43]
reported that sedating antihistamines (e.g.,
hydroxyzine, diphenhydramine) are often
beneficial in patients who suffer from exacer-
bations of pruritus at night. Furthermore, Endo
et al. [44] demonstrated that azelastine
hydrochloride, a nonsedating antihistamine,
can alleviate nocturnal scratching and sleep
disturbance in the early period of sleep of
patients, especially in patients with a serum
immunoglobulin (Ig) E C1000 IU/ml. However,
‘sleep time’ or ‘pre-sleep’ time did not differ
significantly. Doxepin is a tricyclic antidepres-
sant with high histamine H1 receptor antago-
nist activity and sedative effects. A small study
in adults with AD found that tricyclic antide-
pressants decrease sleep latency and wakeful-
ness after sleep onset, but did not help with
nocturnal pruritus [45].
Systemic Immunomodulatory Therapy
Weatherhead et al. [46] showed that
methotrexate is an effective, well-tolerated
treatment for moderate-to-severe AD and can
result in significant improvements in pruritus
and sleep loss (P\0.05 for both). Similarly,
Berth-Jones et al. [47] demonstrated that aza-
thioprine can significantly improve pruritus
(P\0.003) and sleep disturbance (P\0.01).
Dupilumab (DUPIXENT) was approved by
the US Food and Drug Administration (FDA) for
treatment of moderate-to-severe atopic der-
matitis on 28 March 2017 [48]. During clinical
trials, significant improvement in sleep were
reported with dupilumab in 1–2 weeks relative
to placebo (P\0.05) and were maintained over
the treatment duration (except for the 100-mg
q4w dose) based on sleep items from the
SCORAD and Patient-Oriented Eczema Measure
(POEM) [18]. For pruritus, significant improve-
ments relative to placebo (P\0.05) were
reported on the pruritus Numeric Rating Scale
(NRS) at all doses as early as week 1 and
remained significant throughout the study.
Supplements
Though no data are available for adults, Chang
et al. [49] recently evaluated the effectiveness of
melatonin supplementation in children with
AD and demonstrated that it is a safe and
effective way to improve sleep-onset latency
(sleep-onset latency shortened by 21.4 min after
melatonin treatment compared with after pla-
cebo; P = 0.02) and disease severity by SCORAD
(SCORAD decreased by 9.1 compared with after
placebo; P\0.001).
Mehrbani et al. [50] demonstrated that the
use of whey with the aqueous extract of field
dodder (Cuscuta campestris Yunck) seeds in sev-
ere and refractory AD patients can significantly
improve pruritus (P\0.001) and sleep distur-
bance (P\0.05). A study by Itamura et al. [51]
found that individualized homeopathic treat-
ment provokes good response in AD patients,
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including improvement in pruritus and sleep
(significance of data was not shown).
Other
Barbeau et al. [52] reported that 18 out of 41
patients with severe AD take medication for
sleep. However, Yu et al. [17] did not find sta-
tistically significant odds of increased sleeping
pill (unspecified type) use in AD patients vs. the
control group (OR: 1.40; P = 0.18). San-
chez-Perez et al. [20] found no specific pattern
of sleeping pill use (unspecified type) based on
AD severity. A double-blind, placebo-con-
trolled, crossover study in adults with AD
showed that benzodiazepines can increase total
sleep time but can disrupt the sleep architecture
and did not reduce total nocturnal scratching
[53].
DISCUSSION
A comprehensive review of the literature
showed that there is a high prevalence
(33–87.1%) of sleep disturbance in adults with
AD [17, 18, 20]. The likelihood of sleep distur-
bance is much higher in patients with AD
compared to healthy controls [2, 17]. Sleep
disturbance appears to worsen with AD severity
[19, 20, 24, 26, 29]. Although various studies
showed mixed results, overall, adults with AD
experience lower sleep quality as evidenced by
difficulty falling asleep, greater frequency and
duration of waking episodes, and shorter sleep
duration. Such disturbances can consequently
lead to daytime sleepiness, fatigue, and dys-
function. Adult patients with AD and associated
sleep disturbance can experience difficulties
with IADLs and may have more missed work-
days, days in bed, and doctor visits
[2, 17, 26, 27], which may contribute to
decreased QoL. These findings illustrate the
importance of addressing sleep disturbances in
patients with AD as part of routine disease
management.
The current literature review found pruritus
and scratching to be a large contributor to sleep
disturbance in adult patients with AD. Pruritus
appears to be associated with lower quality of
sleep [24] with more frequent and longer
duration of awakenings. Scratching also brings
one to a more superficial stage of sleep.
Scratching mainly occurs in N1 and N2 stages of
NREM sleep [26, 31], which have the lowest
arousal threshold but are essential for ‘‘restora-
tive’’ sleep. Pruritus in AD is associated with a
negative impact on QoL as measured by vali-
dated instruments such as the DLQI and Euro-
QoL-5 dimensions visual analog scale (EQ-5d
VAS) [23]. A better understanding of the
mechanism of pruritus and therapies may
improve QoL in adult patients with AD and
sleep disturbance.
Small numbers of studies suggest that sleep
disturbance is associated with increased type 2 T
helper (Th2) cell pathway activation in AD
patients, which can worsen skin disease, leading
to a self-perpetuating cycle of itch-scratch-sleep
loss. However, current evidence does not clearly
describe the extremely complex relationship
between sleep disturbance and cytokines in AD.
Many cytokines have been implicated in the
pathogenesis of AD, and a small number of
studies show that these cytokines may overlap
or interact with those that regulate or influence
sleep. Bender et al. [26] found that the morn-
ing-evening change of interleukin (IL)-6, tumor
necrosis factor (TNF)-a, and IL-10 produced by
peripheral mononuclear cells and stimulated by
anti-CD3 correlates with sleep efficiency as
measured by actigraphy in adults with AD. This
suggests that higher levels of inflammatory
cytokines are associated with poor sleep effi-
ciency, a finding that is also seen in other dis-
eases such as rheumatoid arthritis and
inflammatory bowel disease [54, 55]. Other
studies have found that the ratio of interferon
(IFN)-c to IL-4 is lower in children with AD
experiencing poor sleep efficiency and that
morning blood plasma levels of IL-31 correlated
with sleep disturbance, specifically in N1 sleep
[56, 57].
Interestingly, inflammation and sleep are
linked by central and peripheral circadian
mechanisms [58], which not only regulate
melatonin and sleep-wake cycles, but also affect
inflammatory cells, cytokines [59, 60], and
intrinsic skin properties such as pH, water loss,
and permeability [61–63]. In AD, cyclical
changes in melatonin and cortisol release may
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promote inflammation and exacerbate itch [41].
Nighttime changes in skin physiology and
inflammatory cytokines can, in turn, exacerbate
atopic inflammation, pruritus, and sleep dis-
turbance [58, 61, 64].
Several environmental factors have also been
associated with sleep disturbance in AD. For
example, serum IgE antibodies specific for dust
mite allergens, Derf and Derp, were significantly
correlated with reduced sleep efficiency, longer
sleep onset latency, increased sleep fragmenta-
tion, and decreased non-REM sleep in children
with eczema [65]. High concentrations of dust
mite allergen are found on beds and may be a
source of exposure during sleep. In children
with AD from the German LISAplus cohort,
exposure to mold or visible dampness was also
associated with increased risk of sleep problems,
including difficulty falling asleep, difficulty
staying asleep, and decreased overall sleep time
[66]. Currently, there is a lack of studies exam-
ining the impact of environmental factors on
sleep in adults with AD. Future research in this
area may identify modifiable aspects of the liv-
ing environment that can improve sleep and
QoL in adults.
Despite the obvious importance of evaluat-
ing sleep, there is currently no reliable tool
designed specifically for AD patients to assess
sleep in the clinical setting. It is important to
note that sleep disturbance is a parameter that is
included in the calculation of total points on
the SCORAD; this can give rise to bias in favor
of reported correlations between both sleep
disturbance and AD activity in the clinical and
research settings. PSG and actigraphy are not
practical for utilization in a dermatology prac-
tice. Widely used, validated dermatology QoL
surveys such as DLQI [67] identify sleep distur-
bance only as a secondary measure and do not
focus on assessing the degree of sleep distur-
bance or offer much insight into treatment
options. Furthermore, available patient QoL
measurement scales are considered less practical
and are not recommended for routine clinical
practice [68]. However, administering a brief
sleep questionnaire (e.g., PSQI) prior to the first
visit in all new patients and then on subsequent
follow-up visits may be worthwhile to follow
improvement with management of AD [69]. At
a minimum, clinicians should evaluate the
patients’ severity of AD and ask general ques-
tions about itch, sleep, impact on daily activi-
ties, and persistence of disease. If a patient
complains of sleep disturbance, clinicians can
take a basic sleep history focusing on the five
major domains of sleep: sleep onset, latency,
quality, efficiency, snoring, or difficulty
breathing. A useful mnemonic used as a
screening tool in children is BEARS (B = bed-
time problems, E = excessive daytime sleepi-
ness, A = awakenings during the night,
R = regularity and duration of sleep, S = snoring
or difficulty breathing), which can be useful to
quickly assess different domains of sleep [70].
Furthermore, it may also help rule in or out
other possible causes that may be contributing
to sleep disturbance, such as an unhealthy sleep
hygiene or an underlying sleep disorder, and
make appropriate recommendations if neces-
sary. A referral to a specialist for sleep evalua-
tion can be considered when a patient regularly
has trouble with sleep disturbance despite
addressing one or more of these factors.
Optimal management of sleep health in AD
requires a multidisciplinary approach. One
aspect of improving sleep involves targeting
pruritus, which can drive sleep disturbance in
AD. Generally, the least invasive treatments
should be tried first. Patient education on
breaking the itch-scratch cycle has been used to
address sleep disruption [71]. Topical emollients
can significantly improve itch and conse-
quently sleep quality [35]. Addition of
chlorhexidine-soaked dressing ‘‘wet wrap’’ may
also be helpful [37]. Similarly, topical corticos-
teroids with or without use of emollients and
systemic agents for AD such as methotrexate
[46] and azathioprine [47] are also shown to be
beneficial for improving itch and sleep in AD
patients. Dupilumab is a new biologic agent
that also has been shown to significantly
improve pruritus and sleep during clinical trials
[18]. Antihistamines used to treat pruritus have
sedative effects and can therefore also improve
sleep [40, 42–44, 50]. On the other hand, the
use of benzodiazepines is not well studied and
may not improve sleep in adult AD patients
[51]. Other interventions focus directly on sleep
disturbance itself. For example, psychological
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therapy aimed at improving sleep hygiene,
promoting relaxation, and establishing behav-
ior plans for addressing sleep problems may
reduce loss of sleep in chronic itch [72, 73]. In
addition to behavioral interventions, melatonin
has been shown to be a safe and effective way to
improve sleep-onset latency in pediatric
patients with AD [49].
CONCLUSIONS
A review of the current literature shows that
there is a high prevalence of sleep disturbance
experienced by adults with AD, which can have
a significant impact on QoL. It is important that
clinicians evaluate the severity of AD and ask
general questions about itch, sleep, impact on
daily activities, and persistence of disease dur-
ing each patient visit and follow-up with com-
plains of sleep disturbance. Management of
sleep disturbance in AD should focus on ade-
quate disease control of AD as well as possible
medical interventions to help improve sleep.
The pathophysiology of sleep disturbance in AD
is extremely complex, and further research is
needed to better understand the interplay of the
immune system, circadian rhythm, and envi-
ronmental factors implicated in both AD and
sleep.
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